200 infants were equally randomized to receive 10ug of group C meningococcal oligosaccharide conjugated to CRM197 (menC-CRM) or a control vaccine at 2, 4, and 6 mo. of age. DTP/HbOC and OPV were administered concurrently. Group C meningococcal IgG antibody was measured by standardized EIA methods.

Pre-vaccination serum GMT to menC was 0.06-0.09 ug/ml. Post-vaccination antibody responses from the first 123 infants are shown:Table Immune responses to HbOC were the same in the menC-CRM and control groups.

Table 1
Full size table

Safety data are under code but local reactions were ≤ those in the DTP/HbOC leg.

We conclude that menC-CRM vaccine is safe and very immunogenic in young infants.